These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 9384246

  • 21. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
    Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G.
    Proc Natl Acad Sci U S A; 1999 Nov 23; 96(24):14136-41. PubMed ID: 10570211
    [Abstract] [Full Text] [Related]

  • 22. Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation.
    Selley DE, Rorrer WK, Breivogel CS, Zimmer AM, Zimmer A, Martin BR, Sim-Selley LJ.
    J Neurochem; 2001 May 23; 77(4):1048-57. PubMed ID: 11359870
    [Abstract] [Full Text] [Related]

  • 23. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth.
    Fride E, Ginzburg Y, Breuer A, Bisogno T, Di Marzo V, Mechoulam R.
    Eur J Pharmacol; 2001 May 11; 419(2-3):207-14. PubMed ID: 11426843
    [Abstract] [Full Text] [Related]

  • 24. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
    Lay L, Angus JA, Wright CE.
    Eur J Pharmacol; 2000 Mar 10; 391(1-2):151-61. PubMed ID: 10720647
    [Abstract] [Full Text] [Related]

  • 25. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
    Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D, Makriyannis A.
    J Med Chem; 1998 Dec 31; 41(27):5353-61. PubMed ID: 9876105
    [Abstract] [Full Text] [Related]

  • 26. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats.
    Di Marzo V, Berrendero F, Bisogno T, González S, Cavaliere P, Romero J, Cebeira M, Ramos JA, Fernández-Ruiz JJ.
    J Neurochem; 2000 Apr 31; 74(4):1627-35. PubMed ID: 10737621
    [Abstract] [Full Text] [Related]

  • 27. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
    Welch SP, Huffman JW, Lowe J.
    J Pharmacol Exp Ther; 1998 Sep 31; 286(3):1301-8. PubMed ID: 9732392
    [Abstract] [Full Text] [Related]

  • 28. Internalization and recycling of the CB1 cannabinoid receptor.
    Hsieh C, Brown S, Derleth C, Mackie K.
    J Neurochem; 1999 Aug 31; 73(2):493-501. PubMed ID: 10428044
    [Abstract] [Full Text] [Related]

  • 29. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds.
    Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, Takayama H, Waku K, Seki C, Baba N, Ishima Y.
    J Biol Chem; 1999 Jan 29; 274(5):2794-801. PubMed ID: 9915812
    [Abstract] [Full Text] [Related]

  • 30. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.
    Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF, Lichtman AH.
    J Pharmacol Exp Ther; 2013 Jun 29; 345(3):492-501. PubMed ID: 23412396
    [Abstract] [Full Text] [Related]

  • 31. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
    Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG.
    Br J Pharmacol; 2005 Dec 29; 146(7):917-26. PubMed ID: 16205722
    [Abstract] [Full Text] [Related]

  • 32. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures.
    Molina-Holgado F, Molina-Holgado E, Guaza C, Rothwell NJ.
    J Neurosci Res; 2002 Mar 15; 67(6):829-36. PubMed ID: 11891798
    [Abstract] [Full Text] [Related]

  • 33. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine.
    Ross RA, Brockie HC, Fernando SR, Saha B, Razdan RK, Pertwee RG.
    Br J Pharmacol; 1998 Nov 15; 125(6):1345-51. PubMed ID: 9863666
    [Abstract] [Full Text] [Related]

  • 34. Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats.
    Drew LJ, Harris J, Millns PJ, Kendall DA, Chapman V.
    Eur J Neurosci; 2000 Jun 15; 12(6):2079-86. PubMed ID: 10886347
    [Abstract] [Full Text] [Related]

  • 35. Inhibitory effects of SR141716A on G-protein activation in rat brain.
    Sim-Selley LJ, Brunk LK, Selley DE.
    Eur J Pharmacol; 2001 Mar 02; 414(2-3):135-43. PubMed ID: 11239913
    [Abstract] [Full Text] [Related]

  • 36. Cannabinoid signaling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids.
    Breivogel CS, Walker JM, Huang SM, Roy MB, Childers SR.
    Neuropharmacology; 2004 Jul 02; 47(1):81-91. PubMed ID: 15165836
    [Abstract] [Full Text] [Related]

  • 37. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice.
    Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G.
    Proc Natl Acad Sci U S A; 2003 Feb 04; 100(3):1393-8. PubMed ID: 12538878
    [Abstract] [Full Text] [Related]

  • 38. Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors.
    Paria BC, Ma W, Andrenyak DM, Schmid PC, Schmid HH, Moody DE, Deng H, Makriyannis A, Dey SK.
    Biol Reprod; 1998 Jun 04; 58(6):1490-5. PubMed ID: 9623610
    [Abstract] [Full Text] [Related]

  • 39. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
    Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V.
    Endocrinology; 2000 Jan 04; 141(1):118-26. PubMed ID: 10614630
    [Abstract] [Full Text] [Related]

  • 40. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
    Derocq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Ségui M, Casellas P.
    FEBS Lett; 1998 Apr 03; 425(3):419-25. PubMed ID: 9563506
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.